Graft vs Leukemia Effect

Contact Us
If you have any questions or feedback please contact us.

"Graft vs Leukemia Effect" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Immunological rejection of leukemia cells following bone marrow transplantation.

Descriptor ID	D020544
MeSH Number(s)	G12.875.402.320.320
Concept/Terms	Graft vs Leukemia Effect Graft vs Leukemia Effect Graft-vs-Leukemia Response Graft-vs-Leukemia Responses Response, Graft-vs-Leukemia Responses, Graft-vs-Leukemia Graft vs Leukemia Response Graft-vs-Leukemia Effect Effect, Graft-vs-Leukemia Effects, Graft-vs-Leukemia Graft-vs-Leukemia Effects

Below are MeSH descriptors whose meaning is more general than "Graft vs Leukemia Effect".

Biological Sciences [G]
Immune System Phenomena [G12]
Transplantation Immunology [G12.875]
Graft vs Host Reaction [G12.875.402]
Graft vs Tumor Effect [G12.875.402.320]
Graft vs Leukemia Effect [G12.875.402.320.320]

Below are MeSH descriptors whose meaning is related to "Graft vs Leukemia Effect".

Below are MeSH descriptors whose meaning is more specific than "Graft vs Leukemia Effect".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Graft vs Leukemia Effect" by people in this website by year, and whether "Graft vs Leukemia Effect" was a major or minor topic of these publications.

To see the data from this visualization as text, click here.

Below are the most recent publications written about "Graft vs Leukemia Effect" by people in Profiles.

Chung YJ, Fry TJ, Aplan PD. Myeloablative hematopoietic stem cell transplantation improves survival but is not curative in a pre-clinical model of myelodysplastic syndrome. PLoS One. 2017; 12(9):e0185219.

View in: PubMed
Shah NN, Loeb DM, Khuu H, Stroncek D, Ariyo T, Raffeld M, Delbrook C, Mackall CL, Wayne AS, Fry TJ. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse. Biol Blood Marrow Transplant. 2016 12; 22(12):2149-2154.

View in: PubMed
Shah NN, Baird K, Delbrook CP, Fleisher TA, Kohler ME, Rampertaap S, Lemberg K, Hurley CK, Kleiner DE, Merchant MS, Pittaluga S, Sabatino M, Stroncek DF, Wayne AS, Zhang H, Fry TJ, Mackall CL. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. Blood. 2015 Jan 29; 125(5):784-92.

View in: PubMed
Marcondes AM, Karoopongse E, Lesnikova M, Margineantu D, Welte T, Dinarello CA, Hockenbery D, Janciauskiene S, Deeg HJ. a-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics. Blood. 2014 Oct 30; 124(18):2881-91.

View in: PubMed
Shand JC, Qin H, Nasholm N, Capitini CM, Fry TJ. Minor antigen distribution predicts site-specific graft-versus-tumor activity of adoptively transferred, minor antigen-specific CD8 T Cells. Biol Blood Marrow Transplant. 2014 Jan; 20(1):26-36.

View in: PubMed
Verneris MR. Natural killer cells and regulatory T cells: how to manipulate a graft for optimal GVL. Hematology Am Soc Hematol Educ Program. 2013; 2013:335-41.

View in: PubMed
Gutman JA, Turtle CJ, Manley TJ, Heimfeld S, Bernstein ID, Riddell SR, Delaney C. Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit. Blood. 2010 Jan 28; 115(4):757-65.

View in: PubMed
Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH, Burke MJ, Blazar BR, Miller JS, McGlave PB, Weisdorf DJ, Wagner JE. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood. 2009 Nov 05; 114(19):4293-9.

View in: PubMed
Young FM, Campbell A, Emo KL, Jansson J, Wang PY, Jordan CT, Mullen CA. High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells. Biol Blood Marrow Transplant. 2008 Jun; 14(6):622-30.

View in: PubMed
Gore L, Stelljes M, Stelljes M, Quinones R. Forodesine treatment and post-transplant graft-versus-host disease in two patients with acute leukemia: facilitation of graft-versus-leukemia effect? Semin Oncol. 2007 Dec; 34(6 Suppl 5):S35-9.

View in: PubMed

Top Journals